Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01670617Not ApplicableUnknown

DeNovo NT Natural Tissue Graft Stratified Knee Study

Role: lead

NCT01329445Unknown

DeNovo NT Longitudinal Data Collection (LDC) Knee Study

Role: lead

NCT01347892Unknown

DeNovo NT Ankle LDC Study

Role: lead

NCT00791245Completed

Post Market Study of DeNovo NT, Natural Tissue Graft

Role: lead

NCT01410136Not ApplicableTerminated

Chondrofix Osteochondral Allograft Prospective Study

Role: lead

All 5 trials loaded